NuvalentNUVL
NUVL
About: Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Employees: 127
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
88% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 25
42% more capital invested
Capital invested by funds: $5.04B [Q2] → $7.15B (+$2.11B) [Q3]
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
22% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 11 (+2) [Q3]
12% more funds holding
Funds holding: 172 [Q2] → 192 (+20) [Q3]
3.75% less ownership
Funds ownership: 112.39% [Q2] → 108.64% (-3.75%) [Q3]
30% less call options, than puts
Call options by funds: $46.7M | Put options by funds: $66.5M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$110
34%
upside
Avg. target
$122
48%
upside
High target
$134
63%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 32% 1-year accuracy 61 / 188 met price target | 34%upside $110 | Buy Reiterated | 17 Jan 2025 |
BMO Capital Etzer Darout 22% 1-year accuracy 9 / 41 met price target | 63%upside $134 | Outperform Maintained | 13 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-year for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population, with topline pivotal data anticipated in the first half of 2025 Topline pivotal data for neladalkib (NVL-655) in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 th at 9:00 a.m.
Positive
Seeking Alpha
2 weeks ago
Nuvalent: A Logical Acquisition Target
Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results and FDA designations. Nuvalent's robust financial position and pipeline make it a prime M&A target, with potential suitors like Pfizer, AstraZeneca, and Novartis. Downside risks include regulatory setbacks, commercialization challenges, strong competition, and financial management, but Nuvalent's cash runway is healthy until 2028.
Neutral
PRNewsWire
1 month ago
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Neutral
PRNewsWire
1 month ago
Nuvalent Appoints Grant Bogle to Board of Directors
CAMBRIDGE, Mass. , Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors.
Neutral
PRNewsWire
2 months ago
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass , Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m.
Neutral
PRNewsWire
2 months ago
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory Board Strong cash position of $1.2 billion, including proceeds from upsized $575 million public offering, expected to extend operating runway into 2028 CAMBRIDGE, Mass.
Positive
Seeking Alpha
4 months ago
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.
Neutral
PRNewsWire
4 months ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100.00 per share.
Positive
Zacks Investment Research
4 months ago
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Positive
Seeking Alpha
4 months ago
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using zidesamtinib for the treatment of patients with ROS-1 mutant NSCLC. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; 3% to 5% are ALK-positive and then 1% to 3% are ROS-1 positive.
Charts implemented using Lightweight Charts™